Evidence map›Paper›PMID 41472057›Full record

ArticleMicroorganisms2025

teamNGS Balances Sensitivity for Viruses with Comprehensive Microbial Detection in Clinical Specimens.

Julie Yamaguchi, Gregory S Orf, Jenna Malinauskas, Maximillian Mata, Sonja L Weiss, Kenn Forberg, Todd V Meyer, Peter O Wiebe, Illya Mowerman, Stanley J Piotrowski and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Julie YamaguchiInfectious Disease Research, Abbott Laboratories, Abbott Park, IL 60064, USA.ORCID 0009-0003-9770-8362
Gregory S OrfInfectious Disease Research, Abbott Laboratories, Abbott Park, IL 60064, USA.ORCID 0000-0002-4853-8518
Jenna MalinauskasInfectious Disease Research, Abbott Laboratories, Abbott Park, IL 60064, USA.
Maximillian MataInfectious Disease Research, Abbott Laboratories, Abbott Park, IL 60064, USA.
Sonja L WeissInfectious Disease Research, Abbott Laboratories, Abbott Park, IL 60064, USA.ORCID 0009-0001-5198-2505
Kenn ForbergInfectious Disease Research, Abbott Laboratories, Abbott Park, IL 60064, USA.
Todd V MeyerInfectious Disease Research, Abbott Laboratories, Abbott Park, IL 60064, USA.
Peter O WiebeInfectious Disease Research, Abbott Laboratories, Abbott Park, IL 60064, USA.
Illya MowermanInfectious Disease Research, Abbott Laboratories, Abbott Park, IL 60064, USA.
Stanley J PiotrowskiInfectious Disease Research, Abbott Laboratories, Abbott Park, IL 60064, USA.
Daniel GlowniaInfectious Disease Research, Abbott Laboratories, Abbott Park, IL 60064, USA.
Mary A RodgersInfectious Disease Research, Abbott Laboratories, Abbott Park, IL 60064, USA.
John HackettInfectious Disease Research, Abbott Laboratories, Abbott Park, IL 60064, USA.
Yupin SuputtamongkolAbbott Pandemic Defense Coalition, Abbott Park, IL 60064, USA.
Pakpoom PhoompoungAbbott Pandemic Defense Coalition, Abbott Park, IL 60064, USA.
Selvamurthi GomathiAbbott Pandemic Defense Coalition, Abbott Park, IL 60064, USA.
Amrose PradeepAbbott Pandemic Defense Coalition, Abbott Park, IL 60064, USA.
Sunil S SolomonAbbott Pandemic Defense Coalition, Abbott Park, IL 60064, USA.
Nicholas BbosaAbbott Pandemic Defense Coalition, Abbott Park, IL 60064, USA.
Pontiano KaleebuAbbott Pandemic Defense Coalition, Abbott Park, IL 60064, USA.
Ambroise D AhouidiAbbott Pandemic Defense Coalition, Abbott Park, IL 60064, USA.
Souleymane MboupAbbott Pandemic Defense Coalition, Abbott Park, IL 60064, USA.
Austin F SequeiraSlieaGen, LLC, Austin, TX 78728, USA.
Arinobu TojoInstitute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
Gavin A ClohertyInfectious Disease Research, Abbott Laboratories, Abbott Park, IL 60064, USA.
Michael G BergInfectious Disease Research, Abbott Laboratories, Abbott Park, IL 60064, USA.ORCID 0000-0003-0233-5819

Funding

Abbott Laboratories N/A
6 · The paper itself

Abstract

Probe-based capture represents a highly sensitive and cost-effective approach for overcoming host background and enriching viruses in metagenomic NGS (mNGS) libraries. Using clinical specimens collected globally from patients with fever or respiratory illness, we generated mNGS libraries by random priming and Nextera XT tagmentation, followed by target enrichment (teNGS) with Comprehensive Viral Research Panel (CVRP) probes. Capture pool sizes and total reads were optimized, and libraries were initially sequenced separately. Using only 3-4% of reads required for standard mNGS, teNGS achieved increased sensitivity, 100-10,000× increases in depth, and >50% genome coverage for pathogens with titers ≥ 1000 cp/mL. Application to >2000 clinical specimens from various matrices and to contrived samples containing viruses absent from the CVRP probe set enabled detection of diverse viral families and established a minimum 65% nucleotide identity for hybridization, respectively. To save time and resources, teNGS and mNGS libraries were then combined into one sequencing run:

Indexed as

metagenomicsnext-generation sequencingtarget enrichmentvirus discovery

Identifiers

PMID41472057
PMCPMC12736096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.